Geistlich Pharma North America Acquires Lynch Biologics
Geistlich Pharma North America announced the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S, the first recombinant growth.
Industry News
Industry News
Osteology Conference Scheduled for February 9-10
With a focus on state-of-the-art regenerative therapies and enhancing success around teeth and implants, the Osteology Foundation and Geistlich Pharma North America will.
